in slowing the progression of neurodegenerative disorders such as Alzheimer's disease.
Introduction
Alzheimer's disease (AD) is still the most common cause of dementia accounting for 50-75 % of all cases [1] , especially in the elderly [2] . As the population of the European continent continues to age, it is predicted that AD will continue to be a major public health problem. Consequently, there is need to identify and develop therapeutic strategies aimed at delaying progression of AD.
Neurodegeneration in AD is linked to the accumulation of senile plaques, which consist of small peptides, known as amyloid-β (Aβ), and intracellular neurofibrillary tangles, consisting of aggregates of hyperphosphorylated tau protein [3] . Neuroinflammation is a process that principally involves activation of astrocytes and microglia by inflammatory mediators in AD [4, 5] . However, in spite of the widely reported roles of microglia and astrocytes in neuroinflammation, it has been suggested that PGE 2 produced in neurons may contribute to the self-propagating processes involved in AD. For instance, Hoshino et al. [6] showed that PGE 2 stimulates the production of Aβ in cultured human neuroblastoma (SH-SY-5Y) cells. Also, reports have demonstrated elevated levels of PGE 2 and COX-2 in the brains of AD patients [7, 8] . Inhibition of PGE 2 production and COX-2 expression therefore provides a critical target for reducing the contributions of neurons to the self-perpetuating cycle of neuroinflammation.
The production of COX-2 and other inflammatory factors is regulated by the transcription factor, nuclear factorkappa B (NF-κB), which has been shown to be widely expressed in the brain. Evidences have been put forward that NF-κB signalling pathways may be activated in AD brains [9] . These have been supported by reports, demonstrating that Aβ peptides could activate NF-κB in neurons [10] . NFκB pathway therefore provides an important target in the understanding of mechanisms involved in modulating inflammation in the neurons.
Accumulation of extracellular Aβ plaques in neurons is one of the important pathological hallmarks in AD. Also, the beta-site amyloid precursor protein (APP) cleaving enzyme1 (BACE-1) plays a key role in the processing of Aβ and its aggregation through catalysing APP [11] . Various studies have demonstrated that the transcription of BACE-1 is controlled by NF-κB and thus Aβ production in neurons [12] [13] [14] [15] . In this regard, targeting BACE-1 and Aβ production could be a potential strategy in slowing down the progression of AD.
Pomegranate fruit (Punica granatum L.) is widely consumed for its broad spectrum of nutritional and health benefits. Pomegranate contains polyphenols and tannins, which have been shown to be responsible for most of its nutritional benefits. Extracts and bioactive constituents of pomegranate fruit have been shown to suppress inflammation. Components such as punicalagin and punicalin have been shown to reduce nitric oxide and PGE 2 production in intestinal cells [16, 17] . In vitro and in vivo studies showed that pomegranate produced significant reduction in egg albumin-induced hind paw inflammation following intraperitoneal and intracerebroventricular administrations in rats, reduction in carrageenan-induced paw oedema, and NO production and iNOS expression in RAW 264.7 cells [18, 19] . Recently, we showed that one of the bioactive components of pomegranate, punicalagin, inhibited neuroinflammation in LPS-activated microglia [20] . In spite of accumulating evidence showing that inflammation in neurons contributes to the pathology in AD, it is not currently known whether pomegranate or its constituents produce any direct effect on these cells. In this study, we have evaluated the activity of freeze-dried pomegranate juice on PGE 2 production in IL-1β-stimulated SK-N-SH cells. In the light of the importance of neuroinflammation to amyloidogenesis, we also investigated whether pomegranate could inhibit BACE-1 and Aβ protein expression in IL-1β-activated neuronal cells.
Materials and methods

Materials
Pomegranate juice (POM Wonderful LLC, Los Angeles, CA) was freeze-dried to a solid sample (PWE), which was then reconstituted in sterile water and stored at −20 °C. Pomegranate juice used in this study was made from fruit skins, which has been standardised to ellagitannins, as punicalagins (80-85 %) and free ellagic acid (1.3 %) as determined by high-performance liquid chromatography [21] .
Cell culture
The human neuroblastoma (SK-N-SH) cells were obtained from the HPA Culture Collection (Salisbury, UK) and were grown in MEM Eagle's medium (Life Technologies, UK). Medium was supplemented with 10 % foetal bovine serum (Sigma, UK), 2 mM l-glutamine, 1 mM sodium pyruvate, 40 units/ml penicillin/streptomycin (Sigma, UK). Confluent monolayers were passaged routinely by trypsinisation. Cultures were grown at 37 °C in 5 % CO 2 until 80 % confluence, and the medium was to serum-free MEM the day before treatment.
HEK293 cells were obtained from the HPA Culture Collection (Salisbury, UK) and were grown in MEM Eagle's medium (Life Technologies, UK). Medium was supplemented with 10 % foetal bovine serum (Sigma, UK), 2 mM l-glutamine, 1 mM sodium pyruvate, 40 units/ml penicillin/streptomycin (Sigma, UK). Confluent monolayers were passaged routinely by trypsinisation. Cultures were grown at 37 °C in 5 % CO 2 until 80 % confluence.
PGE 2 measurement
Quantification of PGE 2 accumulation was carried out in SK-N-SH cells by seeding in 96-well plates (2 × 10 5 / well), cultured for 48 h, and incubated with or without IL-1β (10 U/ml) in the absence or presence of PWE (25-200 μg/ml) for 24 h. PGE 2 concentration was assessed in cell supernatants with a commercially available kit (Arbor Assays, Ann Arbor, MI, USA), followed by measurement at 450 nm with a microplate reader. Experiments were performed at least three times and in triplicate.
Sandwich ELISA for COX-2, phospho-IκBα, and phospho-IKKα Protein expressions of COX-2, phospho-IκBα, and phospho-IKKα were determined using an ELISA for human COX-2, phospho-IκBα, and phospho-IKKα. Cultured SK-N-SH cells were stimulated with IL-1β (10 U/ ml) in the presence or absence of PWE (25-200 μg/ml) for 24 h (COX-2), or 5 min (phospho-IκBα and phospho-IKKα). At the end of the experiments, cells were washed with phosphate-buffered saline (PBS) and lysed with 400 μl cell lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1 % Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 , 1 μg/ml leupeptin] and incubated on ice for 5 min. The cells were then scraped and centrifuged at 13,500 rpm. Cell lysates were collected and measured for levels of COX-2, phospho-IκBα, and phospho-IKKα, using a PathScan ® sandwich ELISA kit (Cell Signalling Technology), according to the manufacturer's instructions.
Transient transfection and luciferase reporter gene assay
In order to determine the effect of PWE on the transactivation of NF-κB, a luciferase reporter gene assay was carried out. HEK293 cells were seeded out at a concentration of 4 × 10 5 cells/ml. Twenty-four hours later, cells were transfected with a Cignal ® NF-κB Reporter (luc) (SABiosciences), using TransIT ® -LT1 transfection reagent (Mirus Bio LLC) and incubated for a further 16 h at 37 °C in 5 % CO 2 . Twenty-four hours later, transfected HEK293 cells were stimulated with TNFα (1 ng/ml) in the presence or absence of PWE (25-200 μg/ml) for 6 h. NF-κB-mediated gene expression was measured with ONE-Glo luciferase assay kit (Promega, Southampton, UK) according to the manufacturer's instructions.
In Cell ELISA for BACE1 and Aβ
In Cell ELISA is used for quantitative protein analysis directly in adherent cell cultures and was used to measure BACE-1 and Aβ protein expression following stimulation of SK-N-SH cells with IL-1β, as described earlier [22] . The protocol was based on the MaxDiscovery In Cell ELISA kit (Bio Scientific, Texas). SK-N-SH cells were seeded out in a 96-well plate (2.5 × 10 5 cells/ml). At 80 % confluence, cells were pre-treated with PWE (25-200 μg/ml) 30 min before stimulation with IL-1β (10 U/ml) for 24 h. At the end of stimulation, cells were washed with 100 μl PBS, fixed, and permeabilised. Primary antibodies (rabbit anti-BACE-1 or rabbit anti-Aβ) were diluted 1:100 and added to each sample well and incubated at room temperature for 1 h. This was followed by incubation with HRP-conjugated anti-rabbit IgG antibody at room temperature for 1 h. TMB solution was added, followed by stop solution and the plate read at 450 nm using a Tecan F50 microplate reader. GAPDH was used as internal control.
Determination of cell viability
Viability of SK-N-SH cells treated with IL-1β (10 U/ml) in the presence or absence of PWE (25-200 μg/ml) was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded in 96-well plates (2 × 10 5 cells/ml) and incubated for 48 h. Thereafter, cells were pre-treated with PWE (25-200 μg/ml) prior to stimulation with IL-1β (10 U/ml). Twenty-four hours after stimulation, culture medium was replaced with MTT solution (5 mg/ml) and incubated for 4 h at 37 °C in 5 % CO 2 . Thereafter, 150 µl of MTT solution was replaced with DMSO and mixed thoroughly on a plate shaker and read at 540 nm.
Cell viability was also measured using the lactate dehydrogenase (LDH) assay [23] . LDH is a cytosolic enzyme that is an indicator of cellular toxicity. When the plasma membrane is damaged, LDH is released into cell culture media. Cells were seeded in 96-well plates (2 × 10 5 cells/ ml) and incubated for 48 h. Thereafter, cells were pretreated with PWE (25-200 μg/ml) prior to stimulation with IL-1β (10 U/ml). Cells were then lysed and supernatants collected for LDH assay. LDH levels in supernatants were determined using the CytoTox 96 ® non-radioactive cytotoxicity assay kit (Promega, Southampton).
Statistical analysis
Values of all experiments were represented as mean ± SEM of at least three experiments. Values were compared using t test (two groups) or one-way ANOVA with post hoc Student-Newman-Keuls test (multiple comparisons). Levels of significance were set at *p < 0.05, **p < 0.01, ***p < 0.001.
Results
PWE reduced PGE 2 production by inhibiting cyclooxygenase-2 (COX-2) protein expression in IL-1β-activated SK-N-SH cells
In the presence of IL-1β (10 U/ml), there was a marked increase (***p < 0.01) in PGE 2 production in supernatants of SK-N-SH cells, when compared to unstimulated cells. However, treatment with PWE (25-200 μg/ml) for 30 min prior to stimulation with IL-1β resulted in significant reduction (***p < 0.001) in PGE 2 production, in comparison with IL-1β control (Fig. 1) . PGE 2 is synthesised through the enzymatic activity of COX-2. Consequently, we sought to determine whether the effect of PWE on PGE 2 was mediated through inhibition of the activities of this enzyme. Interestingly, experiments showed that PWE (25-200 μg/ ml) produced significant reduction (***p < 0.001) in COX-2 protein levels in IL-1β-stimulated SK-N-SH cells (Fig. 2) .
PWE inhibited NF-κB-dependent reporter gene expression in TNFα-activated HEK293 cells
In order to determine the effect of PWE on the transactivation of NF-κB, a luciferase reporter gene assay was carried out. We observed that stimulation of transfected cells with TNFα (1 ng/ml) resulted in activation of the NF-κB-driven luciferase 1 3 expression (Fig. 3) . Pre-incubation with PWE (25 μg/ml) did not affect luciferase expression. However, pre-treatment with 50, 100, and 200 μg/ml of PWE resulted in significant (p < 0.01) and concentration-dependent inhibition of NF-κB-driven luciferase expression, demonstrating that PWE suppresses NF-κB-dependent gene expression in general.
PWE inhibited IL-1β-dependent IκB and IKK phosphorylation in SK-N-SH cells
Based on our observation that PWE inhibited NF-κB-mediated gene expression in general, we sought to investigate its effect on IKK and IκB phosphorylation following stimulation with IL-1β (10 U/ml). Using a sandwich ELISA kit, we observed that IL-1β treatment resulted in phosphorylation of IKK and IκB in IL-1β-treated cells, compared with unstimulated cells. These were significantly inhibited by pre-treatment with 50, 100, and 200 μg/ml of PWE (Figs. 4, 5) .
Pre-treatment of SK-N-SH cells with PWE resulted in inhibition of BACE-1 and Aβ proteins
Exposure of the cells to IL-1β resulted in a marked increase in both BACE-1 and Aβ proteins (Figs. 6, 7) . However, pre-treatment with PWE (50,100, and 200 μg/ 
PWE did not affect the viability of SK-N-SH cells
In order to show that PWE did not affect viability of SK-N-SH cells at concentrations used in this experiment, an MTT assay was performed. Results showed that treatment with PWE (25-200 μg/ml) did not have significant effect on the viability of the cells (Fig. 8a) . LDH assay also showed that concentrations of PWE used for pharmacological investigations did not affect viability (Fig. 8b) . These results suggest that the observed effects of PWE were not due to cytotoxicity as a result of decreased live cells. 
Discussion
Studies on the role of neuroinflammation in AD have focused mainly on the activity of the microglia. However, studies have shown that inflammation in neurons also contributes to the self-perpetuating processes leading to neuronal loss. For example, studies have shown that PGE 2 is able to stimulate Aβ production in SH-SY5Y cells [6] . Furthermore, IL-18 has been shown to increase BACE-1 expression in differentiated SH-SY5Y cells [24] . We therefore investigated whether pomegranate could affect IL-1β-induced PGE 2 production, as well as BACE-1 and Aβ production in SK-N-SH cells. Studies have shown that elevated levels of COX-2 and its metabolic product PGE 2 were observed in AD brains, while COX-2 inhibitors markedly reduce the risk of AD [25] . Recent in vivo studies also show that long-term treatment of APP transgenic mice with NSAIDs significantly diminished inflammatory factors and its dependant Aβ deposition [26] . Our results show that pomegranate significantly inhibited COX-2-mediated PGE 2 production in IL-1β-stimulated SK-N-SH cells, suggesting that pomegranate could reduce the toxic effects of PGE 2 overproduction in neurons.
NF-κB plays a crucial role in regulating the transcription of a wide variety of genes during neuroinflammation and neurodegeneration. In the cytoplasm, NF-κB is coupled with IκB, an inhibitory protein which stays inactive. On activation, IκB undergoes phosphorylation by IKK, resulting in the liberation of NF-κB. This free NF-κB translocates into the nucleus and binds to the promoter region of respective genes such as COX-2. Furthermore, NF-κB activation has been shown to control the transcription of the BACE-1 and APP genes in neurons [13] . To investigate the effect of pomegranate on NF-κB-mediated gene expression in general, a reporter gene assay was carried out. Results show that pomegranate significantly inhibited NF-κB-driven luciferase expression in TNFα-stimulated HEK293 cells, suggesting that this compound is able to attenuate NF-κB-mediated gene expression. To gain a better understanding on the modulatory action of pomegranate on NF-κB signalling pathway, we studied its activity on upstream protein targets. Results show that pomegranate blocked phosphorylation of IκB and IKK in SK-N-SH neuronal cells stimulated with IL-1β; this outcome might suggest that pomegranate acts through interference with NF-κB pathway in neurons. These results were consistent with the outcome of studies conducted by Romier-Crouzet et al. [27] in human intestinal cells. They reported that polyphenolic aqueous extract of pomegranate significantly suppressed NF-κB-mediated NO, PGE 2 , IL-8 production in IL-1β-activated Caco-2 cells. Our results also reflect the results of studies conducted by Ahmed et al. [28] where it was shown that pomegranate inhibited NF-κB in IL-1β-activated human chondrocytes.
In AD brains, Aβ is generated through proteolysis of APP by β-secretase enzymes. Several studies have identified BACE-1 as an important β-secretase enzyme, which effectively cleaves membrane-bound APP [29] . In vivo studies in transgenic mice have also revealed that BACE-1 is highly involved in Aβ plaque formation, and employing BACE-1 blockers has completely reversed Aβ production [30] . As BACE-1 transcription has been shown to be controlled by NF-κB [13] , and since we have shown that pomegranate inhibits NF-κB signalling in SK-N-SH cells, we investigated whether pomegranate would block BACE-1 protein in IL-1β-stimulated SK-N-SH cells. Expectedly, IL-1β induced marked increase in BACE-1 expression in these cells, and this increase was significantly blocked with pomegranate pre-treatment. Interestingly, pomegranate also inhibited Aβ protein induced by IL-1β, suggesting that its effect is probably mediated through the observed interference with BACE-1 enzymatic activity.
This in vitro evidence of the potential nutritional benefits of pomegranate in AD does not prove bioavailability or in vivo biological activity of pomegranate polyphenols following oral intake in humans. However, bioavailability studies have shown that bioactive polyphenols in pomegranate are absorbed from the gastrointestinal tract. Lei et al. [31] reported that punicalagin and ellagic acid reached a plasma concentration of 30 μg/ml and 213 ng/ ml, respectively, following oral administration in rats. A study in rabbits reported that pomegranate constituents become bioavailable 2 h after oral ingestion of concentrated pomegranate extract, ellagic acid reaching a plasma value of 247 ng/ml [32] . In a human study, Seeram et al. administered 180 ml of pomegranate juice containing 25 mg ellagic acid and 318 mg ellagitannins to a human subject. Results of this study showed that ellagic acid was detected in human plasma at a concentration of 31.9 ng/ ml 1 h after ingestion [33] . Furthermore, ellagitannins in pomegranate have been shown to be metabolised by gut bacteria into urolithins that readily enter systemic circulation. These metabolites appeared in human systemic circulation within a few hours of consumption of pomegranate products, reaching maximum concentrations between 24 and 48 h [34] .
To provide benefits in CNS diseases such as AD, pomegranate polyphenols must permeate the blood-brain barrier (BBB). It is not yet clear whether biologically active levels of these compounds could be detected in the CNS following oral administration. However, a study by Farbood et al. [35] showed that oral administration of 100 mg/kg ellagic acid for 7 days prevented cognitive and long-term potentiation deficits in rats. The outcome of this study suggests that ellagic acid permeated the BBB to act in the CNS.
Our study did not establish if the concentrations of pomegranate used in the experiments contain quantities of ellagic acid and ellagitannins which reflect levels which have been detected in plasma. However, we can conclude that bioactive polyphenols in pomegranate could be absorbed from the gastrointestinal tract.
In conclusion, we have provided further data, showing that pomegranate inhibits induced inflammation in SK-N-SH cells. It appears that the effects of pomegranate on inflammatory processes in SK-N-SH cells result in a reduction in BACE-1 and the neurotoxic Aβ. We propose that pomegranate is a potential nutritional strategy in slowing the progression of neuroinflammatory diseases such as AD, possibly through its anti-inflammatory effect. Further pharmacokinetic studies in animals and humans are needed to confirm whether pomegranate polyphenols permeate the BBB and reach biologically active levels in the brain.
